Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Therapeutic Category
Hypertension/ Blood Pressure, Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹99/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Olmetyle H 40 Tablet is a fixed-dose combination of Olmesartan Medoxomil, a potent angiotensin II receptor blocker (ARB), and Hydrochlorothiazide, a thiazide diuretic. This dual therapy provides a synergistic effect for effective management of moderate to severe hypertension. Olmesartan works by blocking angiotensin II from binding to AT1 receptors, leading to vasodilation, reduced vascular resistance, and improved blood flow. Hydrochlorothiazide complements this action by increasing renal excretion of sodium and water, thereby lowering blood volume and reducing blood pressure. The combination of 40 mg Olmesartan and 12.5 mg Hydrochlorothiazide is typically prescribed for patients whose blood pressure is not adequately controlled with monotherapy. Olmetyle 40H helps lower the risk of complications such as stroke, myocardial infarction, kidney damage, and heart failure associated with long-term uncontrolled hypertension. The sustained antihypertensive effect and once-daily dosing improve patient adherence and provide 24-hour blood pressure control.
Common side effects may include dizziness, headache, fatigue, and mild gastrointestinal disturbances. Hydrochlorothiazide may cause increased urination, dehydration, or electrolyte imbalances such as low potassium (hypokalemia) or sodium levels. Olmesartan can occasionally lead to low blood pressure (hypotension), particularly in volume-depleted patients, and rarely kidney function changes. In some patients, increased uric acid levels or photosensitivity reactions may occur. Monitoring of blood pressure, electrolytes, and kidney function is advised during long-term use.
Olmetyle 40H Tablet is indicated for the treatment of essential hypertension in adults, especially in patients who require combination therapy to achieve optimal blood pressure targets or are unresponsive to single-agent treatment.
Olmetyle 40H Tablet should only be used under the guidance of a qualified healthcare provider. It is contraindicated during pregnancy, particularly in the second and third trimesters, due to the risk of fetal toxicity and death. Caution should be exercised in patients with kidney or liver impairment, severe dehydration, or electrolyte disturbances. Avoid potassium supplements or potassium-sparing diuretics unless prescribed. Alcohol intake should be minimized, as it can enhance the blood pressure-lowering effect and increase dizziness. This medicine is not recommended during breastfeeding. Do not discontinue therapy abruptly without consulting your physician, and maintain regular follow-ups for blood pressure and laboratory monitoring.
Store Olmetyle 40H Tablet in a cool, dry place below 30°C. Keep away from moisture and direct sunlight. Retain in original packaging and keep out of the reach of children. Do not use beyond the expiry date mentioned on the strip.
Composition : Olmesartan 20 mg + Hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan 40 mg + hydrochlorothiazide 12.50 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg tablet
Composition : Olmesartan medoxomil 20 mg + chlorthalidone 12.5 mg tablet
Composition : Olmesartan Medoxomil (20mg) + Cilnidipine (10mg) + Chlorthalidone (12.5mg) Tablet
Composition : Olmesartan Medoxomil (40mg) tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
Composition : Olmesartan medoxomil 40 mg + amlodipine 5 mg tablet
Composition : Olmesartan Medoxomil 20 mg tablet
Composition : Olmesartan medoxomil 20 mg + amlodipine 5 mg + hydrochlorothiazide 12.5 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Olmesartan 40 mg + Hydrochlorothiazide 12.5 mg Tablet is a high-strength combination antihypertensive medication used for the management of moderate to severe hypertension (high blood pressure). It combines Olmesartan, an angiotensin II receptor blocker (ARB), with Hydrochlorothiazide, a diuretic that helps reduce excess fluid and sodium in the body. This dual mechanism provides effective and sustained blood pressure control, making it a key product in the cardiology and cardiovascular care segment, with strong demand in the PCD pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand from cardiologists, physicians, and general practitioners. Due to the rising prevalence of hypertension and long-term therapy requirements, this combination offers steady prescriptions, repeat purchases, and strong market stability.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiac and antihypertensive segment with monopoly rights, quality-assured manufacturing standards, attractive promotional support, and reliable supply chain assistance for distributors and franchise partners.
Wholesalers and distributors benefit from strong prescription demand, long-term patient adherence, increasing cardiovascular healthcare needs, and continuous institutional requirements, making this product a profitable and sustainable addition to their pharmaceutical portfolio when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in cardiovascular and antihypertensive formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, promotional support, and PCD pharma franchise opportunities in the cardiac segment.